Bristol Myers Squibb — Ozanimod and S1P Modulation

Company Overview

Company Overview

Bristol Myers Squibb (BMS) acquired Celgene in 2019, gaining the S1P receptor modulator franchise including ozanimod (Zeposia) — a highly selective [sphingosine-1-phosphate (S1P) receptor](/mechanisms/sphingolipid-signaling-neurodegeneration) modulator with improved selectivity over earlier-generation agents. BMS's interest in neurodegeneration through S1P modulation connects to the broader [ceramide/sphingolipid pathway](/mechanisms/ceramide-signaling-neurodegeneration), as S1P receptors sit downstream of the ceramide-sphingosine-S1P metabolic axis.

Ozanimod's high selectivity for S1PR1 and S1PR5 with minimal activity at S1PR2-4 makes it a uniquely differentiated S1P modulator for potential CNS applications["@scott2016"].

Ozanimod: Profile and Mechanism

S1P Receptor Selectivity

Ozanimod is a selective S1PR1 and S1PR5 agonist with approximately 30-fold selectivity for these receptors over S1PR2-4[@cohen2019].

| Receptor | Expression | Ozanimod Activity |
|----------|------------|-------------------|
| S1PR1 | Lymphocytes, astrocytes, neurons | Agonist (internalization) |
| S1PR2 | Oligodendrocytes, microglia | No significant activity |
| S1PR3 | Astrocytes, neurons, heart | No significant activity |
| S1PR4 | Immune cells, brain | No significant activity |
| S1PR5 | Oligodendrocytes, neurons | Agonist |

Mechanism of Action

Sphingolipid Pathway Connection

Ceramide → Sphingosine → S1P → S1PR1/5 → ↓ Neuroinflammation, ↑ Neuroprotection
↑ ↓
Ceramidases S1P modulators (ozanimod)

Ozanimod modulates the [sphingolipid rheostat](/mechanisms/sphingolipid-metabolism-neurodegeneration), shifting the balance toward S1P-mediated neuroprotection while reducing ceramide-driven apoptosis.

Clinical Development

Approved Indications

Ozanimod (Zeposia):

• Relapsing forms of multiple sclerosis (RMS) — FDA approved March 2020
• Moderately to severely active ulcerative colitis — FDA approved May 2021

Neurodegeneration Trials

| Trial | Phase | Indication | Status |
|-------|-------|------------|--------|
| Ozanimod in AD | Phase 1 | Alzheimer's disease | Completed (NCT04628735) |

Phase 1 AD Study (NCT04628735):[@zhang2021]

• Safety and tolerability in mild cognitive impairment due to AD
• Biomarker endpoints: CSF amyloid/tau, neuroinflammation markers
• Results: Safe and well-tolerated; biomarker analyses ongoing

Clinical Trial Details

Sun起Derme Trial Design Considerations:

• Patient population: Early AD (MCI due to AD)
• Dose: Standard MS dose (0.5 mg daily after titration)
• Endpoints: Cognitive testing, CSF biomarkers, MRI

Preclinical Evidence

Neuroprotection Studies

| Study | Model | Key Findings |
|-------|-------|--------------|
| Zhang et al., 2021 | Mouse model | Ozanimod reduced neuroinflammation markers |
| Fazio et al., 2020 | Astrocyte cultures | Modulated astrocyte reactivity, reduced inflammatory cytokine production |
| Chun et al., 2017 | EAE model | Demonstrated anti-inflammatory effects in neuroinflammation |

CNS Penetration

Ozanimod demonstrates moderate CNS penetration:

• Brain-to-plasma ratio: ~0.3-0.5
• CSF concentrations measurable at therapeutic doses
• Direct CNS effects documented in preclinical models

Competitive Landscape

S1P Modulator Comparison

| Agent | Company | S1PR Selectivity | CNS Pen. | Neurodegeneration Development |
|-------|---------|-----------------|----------|-------------------------------|
| Ozanimod | BMS | S1PR1/5 (high) | Moderate | AD Phase 1 |
| Fingolimod | Novartis | S1PR1, 3-5 | Moderate | AD Phase 2, PD Phase 2 |
| Siponimod | Novartis | S1PR1/5 | High | CBS/PSP Phase 2 |
| Ponesimod | Janssen | S1PR1 (selective) | Moderate | MS only |

BMS Differentiation

• Higher selectivity may translate to improved safety/tolerability
• No first-dose cardiac monitoring (unlike fingolimod) due to no S1PR3 activity
• S1PR5 agonism offers unique oligodendrocyte protection
• Dual immune and CNS effects provide broad therapeutic potential

Pipeline and Future Directions

Current Programs

| Program | Indication | Stage | Notes |
|---------|------------|-------|-------|
| Zeposia (ozanimod) | Multiple sclerosis | Approved | First BMS S1P modulator |
| Zeposia | Ulcerative colitis | Approved | Autoimmune indication |
| Ozanimod AD program | Alzheimer's disease | Phase 1 complete | Biomarker data pending |

Potential Expansion

BMS may pursue additional neurodegeneration indications based on:

• Neuroinflammation modulation
• Oligodendrocyte protection
• Combination potential with other AD agents

Company Infrastructure

BMS neuroscience division capabilities:

• Clinical trial infrastructure for CNS disorders
• Biomarker development expertise
• Partnership capabilities for combination therapies

Cross-References

Related Mechanisms

• [Sphingosine-1-Phosphate Signaling in Neurodegeneration](/mechanisms/sphingolipid-signaling-neurodegeneration)
• [Ceramide Signaling Pathway in Neurodegeneration](/mechanisms/ceramide-signaling-neurodegeneration)

Related Therapeutic Pages

• [Ceramide and Sphingolipid Modulation Therapy](/therapeutics/ceramide-sphingolipid-modulation-therapy)
• [S1P Receptor Modulators in Neurodegeneration](/therapeutics/s1p-receptor-modulators-neurodegeneration)
• [Siponimod for Alzheimer's Disease](/therapeutics/siponimod-alzheimers-disease)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF

Related Analyses:

• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;